Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow
Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline numbers suggest.
Pfizer (NYSE:PFE | PFE Price Prediction) declared its quarterly dividend again on Oct. 6, 2026, at $0.43 per share. That’s the same amount it has paid since early 2025. The board held the payout steady after years of annual raises. The last increase took it from $0.42, a bump of about 2.4%. With shares at $29.58, up 24.96% year to date, the stock still yields roughly 5.80%. That raises the question: can Pfizer keep paying it?
Earnings Cover the Dividend, but Cash Flow Is Thin
Pfizer’s 2026 adjusted EPS guidance is $2.80 to $3.00. Against that guidance, the $1.72 annual dividend works out to a payout ratio of about 57% to 61%. Cash flow looks less comfortable. In 2025, operating cash flow minus capital spending came to about $9.08 billion, while dividends cost $9.77 billion. That means the payout ate up about 108% of free cash flow. In the first half of 2026, free cash flow was roughly $2.48 billion, while the company paid $4.9 billion to shareholders. GAAP profits keep taking hits from write-downs, including a $3.8 billion impairment on Sigvotatug vedotin in the second quarter.
Debt From Pfizer’s Dealmaking Limits Its Options
Total debt rose from $35.8 billion at the end of 2022 to $63.2 billion by June 30, 2026, while cash sat at just $976 million. Management put leverage at 2.7 times and offered no promise that it would fall soon:
“Given the LOE impact over the next few years, we expect leverage to remain around current level or modestly higher through this transition period.”
Buybacks are on hold. Pfizer’s 2026 guidance assumes no share repurchases, and $3.3 billion of authorization remains unused.
Pfizer’s Plan to Replace Revenue Lost to Patent Expirations
Generic and biosimilar competition will cost Pfizer about $1.1 billion in revenue this year, and the larger loss-of-exclusivity (LOE) wave, when key patents expire, is still to come. To offset it, launched and acquired products grew 18% operationally in the second quarter. A patent settlement extends U.S. exclusivity for Vyndamax, a heart-disease drug, to June 2031. Cost programs aim for about $9.7 billion in net savings through 2029. Chief executive Albert Bourla addressed the payout directly on the second-quarter call:
“We feel extremely confident that, even in the most stretched scenarios that we are running, we will be able to maintain our dividend. So I want, once and for all, to make that clear to all: the dividend will be maintained, and eventually, after the LOE period, we will start growing it again.”
He also pointed to a “risk-adjusted, high single-digit revenue CAGR from year-end 2028 through year-end 2033,” with obesity drugs from the Metsera deal aiming for a first approval in 2028.
How Bristol Myers and Merck Compare
Despite its own generic erosion, Bristol-Myers Squibb (NYSE:BMY) still raised its dividend to $0.63 per quarter. That was a 1.6% increase and its 17th consecutive annual raise. Bristol also lifted its 2026 EPS outlook to $6.75 to $7.00. Chief executive Christopher Boerner said, “The Growth Portfolio continues to deliver.”
Merck (NYSE:MRK) is paying the cost of rebuilding its pipeline. One-time charges of $9.0 billion for Cidara and $5.7 billion for Terns pulled its 2026 non-GAAP EPS outlook down to $2.66 to $2.76. Merck can absorb charges of that size from a $360 billion market cap. Pfizer is worth about $168.6 billion.
Verdict: Safe for Now, With No Growth Until the End of the Decade
Adjusted earnings cover the dividend well, and management has staked its credibility on keeping it. Free cash flow, though, has fallen short of the payout, and the debt load leaves little room for error. The current $0.43 looks safe through the patent-expiration years. Pfizer’s own plan also makes clear that raises are unlikely to resume before the 2029 return to growth. Until then, keep an eye on free cash flow coverage and leverage.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
